CN101428086A - Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof - Google Patents
Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof Download PDFInfo
- Publication number
- CN101428086A CN101428086A CNA2008103063030A CN200810306303A CN101428086A CN 101428086 A CN101428086 A CN 101428086A CN A2008103063030 A CNA2008103063030 A CN A2008103063030A CN 200810306303 A CN200810306303 A CN 200810306303A CN 101428086 A CN101428086 A CN 101428086A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- chinese medicine
- medicine preparation
- peptic ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 93
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 208000008469 Peptic Ulcer Diseases 0.000 title claims abstract description 33
- 208000011906 peptic ulcer disease Diseases 0.000 title claims abstract description 26
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 241000218176 Corydalis Species 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 210000003038 endothelium Anatomy 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 21
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 9
- 201000005917 gastric ulcer Diseases 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000036407 pain Effects 0.000 abstract description 6
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 5
- 210000000952 spleen Anatomy 0.000 abstract description 5
- 230000004087 circulation Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 208000007882 Gastritis Diseases 0.000 abstract description 3
- 208000028774 intestinal disease Diseases 0.000 abstract description 3
- 241001078983 Tetradium ruticarpum Species 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 4
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 241000723347 Cinnamomum Species 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 239000003205 fragrance Substances 0.000 abstract 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract 1
- 239000010931 gold Substances 0.000 abstract 1
- 229910052737 gold Inorganic materials 0.000 abstract 1
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 30
- 231100000397 ulcer Toxicity 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 24
- 230000002496 gastric effect Effects 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229960005181 morphine Drugs 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical group CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 210000001187 pylorus Anatomy 0.000 description 9
- 102000057297 Pepsin A Human genes 0.000 description 8
- 108090000284 Pepsin A Proteins 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960002362 neostigmine Drugs 0.000 description 8
- 229940111202 pepsin Drugs 0.000 description 8
- 206010000087 Abdominal pain upper Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 230000005176 gastrointestinal motility Effects 0.000 description 7
- 210000002460 smooth muscle Anatomy 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960001380 cimetidine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- IOYNGCZNYGEZRO-UHFFFAOYSA-N 3-ethyl-n,n,2-trimethyl-1h-indol-5-amine Chemical compound C1=C(N(C)C)C=C2C(CC)=C(C)NC2=C1 IOYNGCZNYGEZRO-UHFFFAOYSA-N 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗消化性溃疡的中药制剂及其制备方法，按照重量份计算，它是以白芍1～10份、白术1～20份、苍术1～20份和吴茱萸1～10份为基本原料药制成的，还可与鸡内金1～10份、元胡1～20份、肉桂1～20份和木香15～20份配伍。与现有技术相比，本发明所提供的中药制剂具有健脾和胃，行气止痛的功效，对胃溃疡、十二指肠溃疡和胃炎、腹痛、腹胀为主要症状的胃、肠疾病具有良好的治疗效果；且在保证药物疗效的前提下，最大限度地减少了患者的服用剂量。The invention discloses a traditional Chinese medicine preparation for treating peptic ulcer and a preparation method thereof, which comprises 1-10 parts of Radix Paeoniae Alba, 1-20 parts of Atractylodes Rhizoma Atractylodes Rhizome, 1-20 parts of Atractylodes Rhizoma Atractylodes Rhizome and 1-10 parts of Evodia rutaecarpa. It is made as the basic raw material medicine, and it can also be compatible with 1-10 parts of gallinaceous gold, 1-20 parts of Yuanhu, 1-20 parts of cinnamon and 15-20 parts of woody fragrance. Compared with the prior art, the traditional Chinese medicine preparation provided by the present invention has the effects of invigorating the spleen and stomach, promoting qi circulation and relieving pain, and has therapeutic effects on gastric ulcer, duodenal ulcer, gastritis, abdominal pain and abdominal distension as the main symptoms of stomach and intestinal diseases. Good therapeutic effect; and under the premise of ensuring the curative effect of the drug, the patient's dosage is minimized.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation for the treatment of peptic ulcer and preparation method thereof, belong to technical field of traditional Chinese medicine pharmacy.
Background technology:
Peptic Ulcers is a kind of common chronic systemic disease, is divided into gastric ulcer and duodenal ulcer, is called peptic ulcer again.Why it is called as peptic ulcer, be because think that previously gastric ulcer and duodenal ulcer are because gastric acid and pepsin are formed to the mucosa autodigestion, in fact gastric acid and pepsin are the one of the main reasons of ulcer, also have other reasons can form Peptic Ulcers.Peptic Ulcers belongs to categories such as motherland's medical science " gastric abscess ", " stomachache due to hyperactive liver-QI attacking the stomach ", " pained ", " acid regurgitation "; " epigastric pain ", " peratodynia ", " stomachache ", " the hungry full consumptive disease " etc. of being called among the people more; Be divided into differences such as cold, hot, eating and drinking without temperance, overstrain, blood stasis according to the cause of disease and carry out determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs.Modern medicine study is thought; Peptic Ulcers be the result that the invasion and attack factor of gastric mucosa surpasses the defence capability of autoprotection factor; the invasion and attack factor mainly comprises gastric acid, pepsin, helicobacter pylori etc., and the protection factor then mainly comprises mucus-bicarbonate barrier and mucosal barrier.In addition, still relevant with factors such as autonomic nervous dysfunctions.Peptic Ulcers is a clinical characters with the rhythmicity upper abdominal pain of outbreak repeatedly, often with heating installation, return acid, sensation such as scorching hot, noisy, even also have and feel sick, vomiting, hematemesis, have blood in stool.The routine administration of peptic ulcer comprises the medicine of the excretory medicine of gastric acid inhibitory, protection gastric mucosa and suppresses the medicine of helicobacter pylorus bacteria growing.
The Chinese patent medicine that is used for the treatment of peptic ulcer at present mainly contains stomach medicament capsule, gastral cavilty relaxation grain, nourishing the stomach Yiganning capsule, wild Soviet Union capsule, Margarita stomach peace ball, Medicinal powder of cuttlefish and firtillary bulb, FUFANG WEINING PIAN etc., these medicines all have certain therapeutical effect or preventive effect to peptic ulcer, but wherein most dosage forms are aging, and taking dose is big.
Summary of the invention:
The objective of the invention is to: a kind of Chinese medicine preparation for the treatment of peptic ulcer and preparation method thereof is provided.The present invention by modern galenic pharmacy research, has set forth the mechanism of action that preparation of the present invention is used for the treatment of peptic ulcer fully, and under the prerequisite that guarantees curative effect of medication, has reduced patient's taking dose to greatest extent in conjunction with modern pharmacology drug efficacy study principle.
The present invention constitutes like this: a kind of Chinese medicine preparation for the treatment of peptic ulcer, according to listed as parts by weight, it is that the base stock medicine is made for 1～10 part with 1～10 part of the Radix Paeoniae Alba, 1～20 part of the Rhizoma Atractylodis Macrocephalae, 1～20 part of Rhizoma Atractylodis and Fructus Evodiae.
Preferred scheme is: according to listed as parts by weight, it is that the base stock medicine is made for 5 parts with 5 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Rhizoma Atractylodis and Fructus Evodiae.
In order further to strengthen drug effect, according to listed as parts by weight, crude drug can also comprise 15～20 parts of 1～10 part of Endothelium Corneum Gigeriae Galli, 1～20 part of Rhizoma Corydalis, 1～20 part of Cortex Cinnamomi and the Radix Aucklandiae.
According to listed as parts by weight, best crude drug is combined as: 18 parts of 5 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Rhizoma Atractylodis, 5 parts of Fructus Evodiaes, 5 parts of Endothelium Corneum Gigeriae Galli, 10 parts of Rhizoma Corydalis, 10 parts of Cortex Cinnamomis and the Radix Aucklandiae.
Described Chinese medicine preparation is oral formulations or sublingual administration preparation, as tablet, hard capsule, granule, soft capsule, drop pill, syrup or sublingual lozenge.
One of preparation method of the Chinese medicine preparation of treatment peptic ulcer of the present invention: weighting raw materials material in proportion, microwave drying, pulverize separately are crossed 100 mesh sieves, and mix homogeneously is made various preparation, promptly then.
Two of the preparation method of the Chinese medicine preparation of treatment peptic ulcer: weighting raw materials material in proportion, mix, add 6～10 times of water gagings, decoct 2～4 times, each 1～3 hour, collecting decoction, filter, it is 1.20 clear paste that filtrate decompression is concentrated into 50 ℃ of relative densities, and drying under reduced pressure is pulverized, cross 100 mesh sieves, get extract powder, make various preparation then, promptly.
Three of the preparation method of the Chinese medicine preparation of treatment peptic ulcer: weighting raw materials material in proportion, mix, with 6～10 times of amount 50% or 80% alcohol reflux 1～3 time, each 1～3 hour, filter, be evaporated to 60 ℃ of relative densities and be 1.35 thick paste, dry below 80 ℃, pulverized 100 mesh sieves, get extract powder, make various preparation then, promptly.
Chinese medicine of the present invention is with refining the forming of eight flavor natural Chinese medicinal herb prescriptions, and Fructus Evodiae is hot in nature in the side, outside the warm spleen of decapacitation warming the liver, also is better than dispersing cold for relieving pain, and the Radix Paeoniae Alba is cold in nature, is good at nourishing blood and seeking, and two medicines are monarch drug altogether, common harmonizing yingfen and weifen; Be aided with Rhizoma Atractylodis, the Rhizoma Atractylodis Macrocephalae, the Radix Aucklandiae, the pain relieving of Endothelium Corneum Gigeriae Galli strengthening the spleen to promote digestion, assistant is with Rhizoma Corydalis, Cortex Cinnamomi promoting the circulation of QI to relieve pain, and all medicines are shared, then reach invigorating the spleen and regulating the stomach, the effect of promoting the circulation of QI to relieve pain; Being mainly used in treatment stomach, duodenal ulcer and gastritis, stomachache, abdominal distention is stomach, the intestinal diseases of cardinal symptom, has good effect.
In order to verify the therapeutic effect of Chinese medicine preparation of the present invention, the applicant has carried out corresponding experimental study, studies show that, bring out gastric ulcer model mouse stomach administration preparation of the present invention for pylorus ligation, acetic acid ulcer rat model and reserpine after, have tangible anti-experimental character ulcer function.The main contents of test are as follows:
1. the pharmacodynamic study of anti-peptic ulcer
1.1 medicine and reagent preparation of the present invention is the homemade powder of applicant, Chinese medicines such as the Radix Paeoniae Alba, Rhizoma Atractylodis, Rhizoma Corydalis, Cortex Cinnamomi are commercially available, mainly purchase in area, the southeast of Guizhou Province, Guizhou Province, the blank group is a distilled water, cimetidine (Dongtai city pharmaceutical factory, lot number 990513,0.2g/2ml), reserpine (red flag pharmaceutical factory of Shanghai Medical Univ, lot number 960802,1mg/1ml).
1.2 animal Wastar rat, body weight 175～250g, Kunming mouse, body weight 18.5～23g; The male and female dual-purpose is provided by Zunyi Medical College's Experimental Animal Center.
1.3 method
1.3.1 preparation 1. of the present invention is to the effect of rat experiment gastric ulcer: 40 of rats are divided into 5 groups (seeing Table 1) at random.Experimental technique: continuous gastric infusion 5d, fasting 48h after the administration in the 3rd day freely drinks water, and cuts open the belly the ligation pylorus under the etherization.Postoperative is gastric infusion (dosage sees Table 1) immediately, and postoperative 18h puts to death animal and gets stomach.10% formaldehyde fixed is cut off stomach along greater gastric curvature, and reference literature is estimated the influence of medicine to ulcer with ulcer index and suppression ratio.2. reserpine is brought out the influence of mouse gastric ulcer: 40 of mices, random packet, fasting 48h before the administration, press gastric infusion 20ml/kg of table 2, subcutaneous injection of reserpine 10mg/kg behind the medicine puts to death mice and gets stomach, formaldehyde fixed behind the 6h, 30min tailing edge greater gastric curvature is cut off stomach, observes the ulcer index on the gastric mucosa.3. to the influence of rat gastric ulcer due to the acetic acid: 40 of rats, grouping and the same 1. item of dosage, rat is under etherization cut open the belly, inject 0.1ml acetic acid through internal diameter 5mm glass tubing to the body of stomach serosal surface, be stained with acetic acid with cotton swab behind the 1min, sew up stomach wall, postoperative gastric infusion early 9 o'clock, late 5 o'clock the 2nd day every day 2 times, 10d continuously.Put to death rat on the 11st day and get stomach, formaldehyde fixed is calculated ulcer index.
1.3.2 preparation of the present invention is freely drunk water to the excretory rat fasting 48h that influences of rat gastric juice, surgical procedure with among the 1.3.1 1., 5h puts to death rat behind the pylorus ligation, collects gastric juice, the centrifugal 10min of 3000 commentariess on classics/min stays supernatant mensuration gastric juice amount.Getting gastric juice 1ml, with the phenol red indicator of doing, drip till the first meeting redness with the N/100 sodium hydroxide, both had been the total acid terminal point.Pepsic mensuration is filled Ovum Gallus domesticus album with reference to the special capillary tube method of wheat with glass capillary, places 85 ℃ of hot water to make protein coagulation, and paraffin sealing protein pipe two ends are standby in the storage refrigerator.Get gastric juice 1ml during test, put in the 50ml conical flask, add 0.05N hydrochloric acid 15ml, shake up, put two of protein pipe into, filled in bottleneck, 37 ℃ of calorstats are hatched 24h.Measure the length (mm) of two ends transparent part in the protein pipe, obtain the meansigma methods of four ends.Pepsin unit=meansigma methods
2* 16.
2. the experiment that the mice intestine movement function is influenced
2.1 medicine and reagent preparation of the present invention is the homemade powder of applicant, Chinese medicines such as the Radix Paeoniae Alba, Rhizoma Atractylodis, Rhizoma Corydalis, Cortex Cinnamomi are commercially available, purchase in area, the southeast of Guizhou Province, Guizhou Province.Preparation of the present invention is made 1.25%, 2.5% suspension with distilled water; Neostigmine methylsulfate is that sky, Shandong good fortune pharmaceutical factory produces (lot number 068331), and morphine hydrochloride is that Shenyang No.1 Pharmaceutical Factory, Dongbei Pharmaceutical Group Co. produces (lot number 002747), and the blank group is a normal saline.
2.2 the animal Kunming mouse, body weight 17～25g, the quality certification: 310101004, provide by Medical University Of Chongqing's Experimental Animal Center.
2.3 experimental technique is got 56 of mices, is divided into 7 groups at random, and 8 every group, first group: the neostigmine group; Second group: neostigmine adds preparation group of the present invention; The 3rd group: the morphine group; The 4th group: morphine adds preparation group of the present invention; The 5th group: preparation group of the present invention (1.25%); The 6th group: preparation group of the present invention (2.5%); The 7th group: normal saline blank group.Laboratory animal fasting 24 hours is freely drunk water, and irritates earlier stomach 2.50%0.1ml/10g preparation suspension of the present invention respectively for second, four, six group, irritates stomach 1.25%0.1ml/10g preparation suspension of the present invention for the 5th group, the 7th group of capacity normal saline such as filling stomach.After the administration 1 hour, first and second group is lumbar injection neostigmine 0.1mg/kg respectively, third and fourth group is lumbar injection morphine 10mg/kg respectively, make the suspension oral gavage of 0.11ml/10g after 20 minutes with 5% charcoal end and 10% arabic gum, irritate stomach and put to death with the cervical vertebra dislocation after 30 minutes, cut open the belly immediately.Digestive tube is intactly extracted from pylorus to rectum end, be not tiled in with not adding traction and measure total length on the glass plate, and the forward position at record charcoal end is to the distance of pylorus, calculate its with the percentage ratio of gastrointestinal tract total length promptly: intestinal propulsion rate=pylorus to charcoal end Front distance/pylorus to ileocecus apart from * 100%.
3. statistical procedures
Measurement data represents that with `x ± s two sample standard deviations relatively with the t check, carry out statistical procedures with Excel software.
4. result
4.1 preparation of the present invention is to the influence of ulcer index and ulcer inhibition rate
The ulcer index of three dosage groups of preparation of the present invention and model group relatively are 41.93%～61.84% to the pyloric ligation ulcers ulcer inhibition rate, and there were significant differences; The acetic acid ulcer inhibition rate is 29.31%～48.76%; To reserpine type ulcer model, preparation of the present invention does not have obvious inhibitory action (P〉0.05, table 1).
Table 1 preparation of the present invention is to the influence (n=8) of gastric ulcer model rat ulcer exponential sum ulcer inhibition rate
Compare * P＜0.05, * * P＜0.01 with model group.
The histopathologic examination of acetic acid ulcer shows: model group ulcer is obvious, and fibrous connective tissue is repaired not obvious, and cell infiltration is obvious; Three groups of ulcer of the high, medium and low dosage of preparation of the present invention all obviously alleviate, and especially high, middle dosage group ulcer area is suitable with the cimetidine group, and most ulcer shoal, and inflammatory cell is few, repair obviously.
4.2 preparation of the present invention is to the influence of gastric secretion and pepsin activity
Compare with model group, the middle and high dosage group of preparation of the present invention has obvious inhibitory action to free acid, and gastric juice amount, total acidity stomach function regulating protease activities are not had obvious influence, the results are shown in Table 2.
Table 2 preparation of the present invention is to the influence (n=8) of gastric secretion and pepsin activity
Compare * P＜0.05, * * P＜0.01 with model group.
4.3 preparation of the present invention causes that to neostigmine excitement of intestinal smooth muscle and morphine cause the influence that gastrointestinal motility suppresses
Preparation of the present invention causes that to neostigmine the intestine movement function that excitement of intestinal smooth muscle and morphine cause that gastrointestinal motility slows down has two-phase regulating action (seeing Table 3).
Table 3 preparation of the present invention causes the influence that excitement of intestinal smooth muscle and morphine cause gastrointestinal motility and suppress (n=8, x ± s) to neostigmine
Compare * P＜0.05, * * P＜0.01 with normal saline blank group; Compare ▲ P＜0.05 with the neostigmine group; Compare with the morphine group, ◆ P＜0.05.
5. conclusion
Preparation of the present invention is had the medicaments compound of effects such as immunomodulating, vasodilator, antiinflammatory, analgesia and forms by some, the applicant adopts the acute and chronic peptic ulcer model of three kinds of different onset mechanism, observe the influence of preparation of the present invention, and study its mechanism of action.Pyloric ligation ulcers ulcer (acute ulcer) is to make gastric juice in the gastric retention behind the pylorus ligation, cause gastric acid, pepsin to corrode due to the eupepsy enhancing, preparation of the present invention is to the inhibitory action of pyloric ligation ulcers ulcer and to the influence of gastric secretion, illustrate that the agent of erosion that weakens gastric acid is the mechanism of action of the anti-pylorus ligation ulcer of this medicine model, but this medicine does not have obvious influence to pepsin activity, and its mechanism of action and H2 receptor antagonist cimetidine are not quite similar.Acetic acid ulcer be acetic acid directly to the erosion of gastric tissue, the chronic ulcer that causes the local blood circulation obstacle to cause, factor such as synthetic, the cell regeneration of DNA is relevant in its repair process and intercellular substance and mucus amount, the cell.Experimental result shows that preparation of the present invention has the good curing effect to this model, illustrate that this medicine has the effect that promotes ulcer healing, and curative effect is suitable with cimetidine.
Gastrointestinal dysfunction is the general name of one group of gastrointestinal syndrome, and based on the gastrointestinal motility dysfunction, peptic ulcer is also often with the gastrointestinal motility dysfunction, mainly shows as stomachache, abdominal distention, early full belch, inappetence, feels sick, symptom such as vomiting.In the preparation of the present invention the Radix Paeoniae Alba overwrought spontaneous contraction has inhibitory action and analgesic activity to intestinal tube; Effective ingredient atractylol in the Rhizoma Atractylodis can promote gastrointestinal motility, and smooth muscle is also had the slight shrinkage effect; Rhizoma Corydalis has pair medmain to cause the effect of contraction to the colon that exsomatizes; Cortex Cinnamomi has significant analgesia role.This experiment is judged the influence of preparation of the present invention to the mouse small intestine motor function by the intestinal propulsion rate, and after the result showed that mouse stomach gives preparation of the present invention (1.25% and 2.5%), with normal saline blank group ratio, small intestinal peristalsis did not have significant change.In the experiment behind the mice lumbar injection neostigmine, because it intends the excitement that the choline effect causes the intestinal smooth muscle, the normal matched group of intestinal propulsion rate increase of mice is obviously improved, this hyperfunction enterokinesia of preparation energy antagonism of the present invention, make it multiple normal, neostigmine adds preparation group of the present invention and compares there was no significant difference with normal normal saline matched group, with neostigmine group comparing difference significance.Morphine can make the downward propulsive wriggle weakness of gastrointestinal smooth muscle by improving the gastrointestinal sphincter tone, and intestinal contents is in the gastrointestinal movement slows down.In the experiment after the mice lumbar injection morphine, the normal normal saline matched group of intestinal propulsion rate obviously slows down, and preparation of the present invention also can this enterokinesia of slowing down of antagonism, and morphine adds preparation group of the present invention and morphine group comparing difference significance.By this experiment confirm, preparation of the present invention does not have remarkable influence to normal intestine movement function, and the intestine movement function that effect causes excitement of intestinal smooth muscle and morphine to cause that gastrointestinal motility slows down to neostigmine plan choline has the two-phase regulating action, can make unusual bowel movement become multiple normal.The gastrointestinal dysfunction of these effect characteristics when alleviating peptic ulcer has positive effect.
Compared with prior art, Chinese medicine preparation provided by the present invention has invigorating the spleen and regulating the stomach, and the effect of promoting the circulation of QI to relieve pain is that stomach, the intestinal diseases of cardinal symptom has excellent curative to gastric ulcer, duodenal ulcer and gastritis, stomachache, abdominal distention; And under the prerequisite that guarantees curative effect of medication, reduced patient's taking dose to greatest extent.
The specific embodiment:
Embodiments of the invention 1: the preparation of tablet:
Take by weighing Radix Paeoniae Alba 5g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g and Fructus Evodiae 5g, microwave drying, pulverize separately are crossed 100 mesh sieves, mix homogeneously, drying for standby; Get 100～3000 milligrams of mixed powders, 0.1～0.40 milligram of magnesium stearate, 4～12 milligrams of carboxymethyl starch sodium, 50～100 milligrams of microcrystalline Cellulose; Mixed powder is mixed with carboxymethyl starch sodium, microcrystalline Cellulose, sieve, make its mixing, add suitable quantity of water or alcohol granulation again, after the drying, granulate adds magnesium stearate, with decompressor with the granule compacting in flakes, promptly gets tablet then.Said preparation is oral, and each 3, every day 3 times.
Embodiments of the invention 2: the preparation of hard capsule:
Take by weighing Radix Paeoniae Alba 10g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g and Fructus Evodiae 10g, mix, add 8 times of water gagings, decoct 3 times, 3 hours for the first time, 2 hours for the second time, 1 hour for the third time, collecting decoction filtered, filtrate decompression concentrate (0.06～-0.08Mpa, 80 ℃) to relative density be the clear paste of 1.20 (50 ℃), drying under reduced pressure (0.08Mpa, 70～80 ℃), pulverize, cross 100 mesh sieves, get extract powder; Get 100～3000 milligrams of extract powders, 0.1～0.30 milligram of magnesium stearate, 4～12 milligrams of carboxymethyl starch sodium, 50～100 milligrams of starch; With extract powder and carboxymethyl starch sodium, starch mix homogeneously, add an amount of alcohol granulation again, drying, granulate adds magnesium stearate, in the gelatine capsule of packing into then, promptly gets hard capsule.Said preparation is oral, and each 3, every day 3 times.
Embodiments of the invention 3: the preparation of granule:
Take by weighing Radix Paeoniae Alba 10g, Rhizoma Atractylodis Macrocephalae 1g, Rhizoma Atractylodis 1g and Fructus Evodiae 10g, mix, measure 50% alcohol reflux 3 times with 8 times, each 2 hours, filter concentrating under reduced pressure (vacuum 0.06～0.08Mpa, 80 ℃ of temperature) to relative density be the thick paste of 1.35 (60 ℃), dry below 80 ℃, pulverized 100 mesh sieves, get extract powder; It is an amount of to get extract powder 1～10 gram, dextrin or sucrose 1～10 gram, correctives (as essence) and sweeting agent (as Aspartane); With extract powder and sucrose/dextrin, correctives and sweeting agent mix homogeneously, add suitable quantity of water or ethanol and make soft material, the granulation of sieving, drying, granulate, packing promptly gets granule.Said preparation is oral, each 5 grams, every day 3 times.
Embodiments of the invention 4: preparation of soft capsule:
Take by weighing Radix Paeoniae Alba 5g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g, Fructus Evodiae 5g, Endothelium Corneum Gigeriae Galli 5g, Rhizoma Corydalis 10g, Cortex Cinnamomi 10g and Radix Aucklandiae 18g, mix, measure 80% alcohol reflux 2 times with 8 times, each 2 hours, filter concentrating under reduced pressure (vacuum 0.06～0.08Mpa, 80 ℃ of temperature) to relative density be the thick paste of 1.35 (60 ℃), dry below 80 ℃, pulverized 100 mesh sieves, get extract powder; It is an amount of to get 100～2000 milligrams of extract powders, poly-ethanol or 100～2000 milligrams in Oleum Glycines, 3～10 milligrams of suspending agents (as tween 80), 3～10 milligrams of emulsifying agents (as propylene glycol) and 50～100 milligrams in gelatin, 10～30 milligrams of glycerol, 50～100 milligrams of purified water and antiseptic (as sodium benzoate); Gelatin is placed glue pot, add purified water, 70 ℃ of following heating make dissolving, add glycerol and antiseptic again, stir, and insulation is left standstill after the vacuum removal of air bubbles; In proportion with extract powder and poly-ethanol/Oleum Glycines, emulsifying agent, suspending agent mix homogeneously, again and the gelatin for preparing place rotation to press the capsule machine to be pressed into soft capsule, typing, drying promptly gets soft capsule.Said preparation is oral, and each 3, every day 3 times.
Embodiments of the invention 5: the preparation of drop pill:
Take by weighing Radix Paeoniae Alba 1g, Rhizoma Atractylodis Macrocephalae 1g, Rhizoma Atractylodis 1g, Fructus Evodiae 1g, Endothelium Corneum Gigeriae Galli 1g, Rhizoma Corydalis 1g, Cortex Cinnamomi 1g and Radix Aucklandiae 15g, mix, add 10 times of water gagings, decoct 2 times, each 2 hours, collecting decoction filters, and filtrate decompression is concentrated into the clear paste that relative density is 1.20 (50 ℃), drying under reduced pressure, pulverize, cross 100 mesh sieves, get extract powder; It is an amount of to get 1～10 milligram of extract powder, 20～40 milligrams of Macrogol 4000s, methyl-silicone oil; Extract powder is added water make even pasty state, add substrate (Macrogol 4000) liquid that dissolves again, heating and melting becomes supernatant liquid, pour in the drop pill device of preheating, system temperature and speed are dripped in control, splash in the methyl-silicone oil condensed fluid, blot condensed fluid after becoming ball, collect drop pill, place in the exsiccator, promptly get drop pill.Said preparation is oral, each 0.2 gram, every day 3 times.
Embodiments of the invention 6: the preparation of syrup:
Take by weighing Radix Paeoniae Alba 10g, Rhizoma Atractylodis Macrocephalae 1g, Rhizoma Atractylodis 20g, Fructus Evodiae 1g, Endothelium Corneum Gigeriae Galli 10g, Rhizoma Corydalis 1g, Cortex Cinnamomi 20g and Radix Aucklandiae 15g, mix, measure 50% alcohol reflux 3 times with 6 times, each 1 hour, filter concentrating under reduced pressure (vacuum 0.06～0.08Mpa, 80 ℃ of temperature) to relative density be the thick paste of 1.35 (60 ℃), dry below 80 ℃, pulverized 100 mesh sieves, get extract powder; Get extract powder 1～20 gram, sodium carboxymethyl cellulose 1.5 grams, saccharin sodium 0.1 gram, correctives (as essence) is an amount of, antiseptic (as sodium benzoate) is an amount of and 100 milliliters of purified water; Sodium carboxymethyl cellulose is dispersed in the hot water, and cooling mixes with the aqueous suspension that contains extract powder, saccharin sodium, correctives and antiseptic then, becomes volume required preparing solution and mix homogeneously, and sterilization back packing promptly gets syrup.Said preparation is oral, each 20ml, every day 3 times.
Embodiments of the invention 7: the preparation of sublingual lozenge:
Take by weighing Radix Paeoniae Alba 1g, Rhizoma Atractylodis Macrocephalae 20g, Rhizoma Atractylodis 1g, Fructus Evodiae 10g, Endothelium Corneum Gigeriae Galli 1g, Rhizoma Corydalis 20g, Cortex Cinnamomi 1g and Radix Aucklandiae 20g, mix, measured 80% alcohol reflux 3 hours with 10 times, filter, being evaporated to relative density is the thick paste of 1.35 (60 ℃), dry below 80 ℃, pulverized 100 mesh sieves, get extract powder; Get 10～400 milligrams of extract powders, can press 40～80 milligrams of sucrose, 0.1～0.3 milligram of magnesium stearate; With extract powder sieve the back with can press sucrose, magnesium stearate mix homogeneously, and use the decompressor tabletting, promptly get sublingual lozenge.The said preparation buccal, each 1, every day 3～5 times.
Claims (9)
- [claim 1] a kind of Chinese medicine preparation for the treatment of peptic ulcer is characterized in that: according to listed as parts by weight, it is that the base stock medicine is made for 1～10 part with 1～10 part of the Radix Paeoniae Alba, 1～20 part of the Rhizoma Atractylodis Macrocephalae, 1～20 part of Rhizoma Atractylodis and Fructus Evodiae.
- [claim 2] is characterized in that according to the Chinese medicine preparation of the described treatment peptic ulcer of claim 1: according to listed as parts by weight, it is that the base stock medicine is made for 5 parts with 5 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Rhizoma Atractylodis and Fructus Evodiae.
- [claim 3] is characterized in that according to the Chinese medicine preparation of the described treatment peptic ulcer of claim 1: according to listed as parts by weight, crude drug also has 15～20 parts of 1～10 part of Endothelium Corneum Gigeriae Galli, 1～20 part of Rhizoma Corydalis, 1～20 part of Cortex Cinnamomi and the Radix Aucklandiae.
- [claim 4] is characterized in that according to the Chinese medicine preparation of the described treatment peptic ulcer of claim 3: according to listed as parts by weight, crude drug also has 18 parts of 5 parts of Endothelium Corneum Gigeriae Galli, 10 parts of Rhizoma Corydalis, 10 parts of Cortex Cinnamomis and the Radix Aucklandiae.
- [claim 5] is characterized in that according to the Chinese medicine preparation of claim 1,2,3 or 4 described treatment peptic ulcers: described Chinese medicine preparation is oral formulations or sublingual administration preparation.
- [claim 6] is characterized in that according to the Chinese medicine preparation of the described treatment peptic ulcer of claim 5: described Chinese medicine preparation is tablet, hard capsule, granule, soft capsule, drop pill, syrup or sublingual lozenge.
- [claim 7] is characterized in that as the preparation method of the Chinese medicine preparation of treatment peptic ulcer as described in each among the claim 1-6: weighting raw materials material in proportion, microwave drying, pulverize separately is crossed 100 mesh sieves, mix homogeneously is made various preparation, promptly then.
- [claim 8] is characterized in that as the preparation method of the Chinese medicine preparation of treatment peptic ulcer as described in each among the claim 1-6: weighting raw materials material in proportion, mix, add 6～10 times of water gagings, decoct each 1～3 hour 2～4 times, collecting decoction filters, and it is 1.20 clear paste that filtrate decompression is concentrated into 50 ℃ of relative densities, drying under reduced pressure, pulverize, cross 100 mesh sieves, get extract powder, make various preparation then, promptly.
- [claim 9] is as the preparation method of the Chinese medicine preparation of treatment peptic ulcer as described in each among the claim 1-6, it is characterized in that: weighting raw materials material in proportion, mix, measure 50% or 80% alcohol reflux 1～3 time with 6～10 times, each 1～3 hour, filter, be evaporated to 60 ℃ of relative densities and be 1.35 thick paste, dry below 80 ℃, pulverized 100 mesh sieves, get extract powder, make various preparation then, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008103063030A CN101428086B (en) | 2008-12-17 | 2008-12-17 | Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008103063030A CN101428086B (en) | 2008-12-17 | 2008-12-17 | Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101428086A true CN101428086A (en) | 2009-05-13 |
| CN101428086B CN101428086B (en) | 2011-07-06 |
Family
ID=40643854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008103063030A Expired - Fee Related CN101428086B (en) | 2008-12-17 | 2008-12-17 | Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101428086B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138999A (en) * | 2011-04-01 | 2011-08-03 | 匡海学 | Medicinal evodia fruit lactone and polysaccharide extracts for treating digestive tract diseases, and preparation method and application thereof |
| CN103110878A (en) * | 2012-12-10 | 2013-05-22 | 宋爱民 | Traditional Chinese medicine preparation for treating gastric upset |
| CN103202891A (en) * | 2013-04-15 | 2013-07-17 | 褚小红 | Weishuning tablet Chinese medicinal composition and preparation method thereof |
| CN103735591A (en) * | 2013-12-12 | 2014-04-23 | 中国科学院昆明植物研究所 | Composition for treating digestive ulcer and applications thereof |
| CN107898887A (en) * | 2018-01-11 | 2018-04-13 | 孟凌冰 | A kind of Chinese medicine for treating helicobacter pylori |
| CN108653690A (en) * | 2018-06-08 | 2018-10-16 | 刘青 | A kind of Chinese medicine composition for treating stomach trouble |
| JP2019019061A (en) * | 2017-07-12 | 2019-02-07 | ライオン株式会社 | Oral liquid pharmaceutical composition and pharmaceutical |
| CN111671858A (en) * | 2020-04-13 | 2020-09-18 | 石家庄市中医院 | Traditional Chinese medicine composition for recovering intestinal tract after enteroscopy and preparation method thereof |
| CN112220864A (en) * | 2020-09-08 | 2021-01-15 | 辛砚忠 | Medicine for treating gastrointestinal diseases and preparation method thereof |
| CN115444885A (en) * | 2022-10-27 | 2022-12-09 | 上海市中医医院 | Traditional Chinese medicine composition for treating spleen and stomach deficiency-cold syndrome after gastric cancer operation and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1421221A (en) * | 2001-11-29 | 2003-06-04 | 田玉芝 | Medicine for treating gastroduodenal ulcer |
| CN1235636C (en) * | 2003-10-07 | 2006-01-11 | 李伟 | Kangning Stomach invigorating capsule |
| CN101264232A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Medicine for treating gastric ulcer and duodenal ulcer and preparation |
-
2008
- 2008-12-17 CN CN2008103063030A patent/CN101428086B/en not_active Expired - Fee Related
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138999A (en) * | 2011-04-01 | 2011-08-03 | 匡海学 | Medicinal evodia fruit lactone and polysaccharide extracts for treating digestive tract diseases, and preparation method and application thereof |
| CN103110878A (en) * | 2012-12-10 | 2013-05-22 | 宋爱民 | Traditional Chinese medicine preparation for treating gastric upset |
| CN103110878B (en) * | 2012-12-10 | 2014-08-13 | 宋爱民 | Traditional Chinese medicine preparation for treating gastric upset |
| CN103202891A (en) * | 2013-04-15 | 2013-07-17 | 褚小红 | Weishuning tablet Chinese medicinal composition and preparation method thereof |
| CN103735591A (en) * | 2013-12-12 | 2014-04-23 | 中国科学院昆明植物研究所 | Composition for treating digestive ulcer and applications thereof |
| CN103735591B (en) * | 2013-12-12 | 2016-04-06 | 中国科学院昆明植物研究所 | A kind of compositions of anti-peptic ulcer and application thereof |
| JP2019019061A (en) * | 2017-07-12 | 2019-02-07 | ライオン株式会社 | Oral liquid pharmaceutical composition and pharmaceutical |
| JP7095235B2 (en) | 2017-07-12 | 2022-07-05 | ライオン株式会社 | Oral liquid pharmaceutical compositions and pharmaceuticals |
| CN107898887A (en) * | 2018-01-11 | 2018-04-13 | 孟凌冰 | A kind of Chinese medicine for treating helicobacter pylori |
| CN107898887B (en) * | 2018-01-11 | 2020-11-24 | 孟凌冰 | Traditional Chinese medicine for treating helicobacter pylori |
| CN108653690A (en) * | 2018-06-08 | 2018-10-16 | 刘青 | A kind of Chinese medicine composition for treating stomach trouble |
| CN111671858A (en) * | 2020-04-13 | 2020-09-18 | 石家庄市中医院 | Traditional Chinese medicine composition for recovering intestinal tract after enteroscopy and preparation method thereof |
| CN112220864A (en) * | 2020-09-08 | 2021-01-15 | 辛砚忠 | Medicine for treating gastrointestinal diseases and preparation method thereof |
| CN115444885A (en) * | 2022-10-27 | 2022-12-09 | 上海市中医医院 | Traditional Chinese medicine composition for treating spleen and stomach deficiency-cold syndrome after gastric cancer operation and application thereof |
| CN115444885B (en) * | 2022-10-27 | 2023-05-30 | 上海市中医医院 | Traditional Chinese medicine composition for treating spleen and stomach deficiency-cold syndrome after gastric cancer operation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101428086B (en) | 2011-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101428086A (en) | Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
| CN103285119A (en) | Chinese medicine composition for treating autoimmune liver disease, and preparation method thereof | |
| CN101002929A (en) | Medicine for treating functional hypopepsia or complicating Helicobacter pylori infection, and its preparing method | |
| CN101757281B (en) | Traditional Chinese medicine composition for treating gastrointestinal disease and preparation method thereof | |
| CN101011562A (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| CN100384463C (en) | Medicine for trenting flooding and spotting, haematemesis and homafecia | |
| CN100391494C (en) | A kind of traditional Chinese medicine compound preparation for treating pain syndrome and preparation method thereof | |
| CN106620475B (en) | Traditional Chinese medicine composition for preventing and treating diabetes cognitive impairment and preparation method thereof | |
| CN101780263A (en) | Traditional Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN102228547A (en) | Application of traditional Chinese medicine composition in preparing medicaments treating pancreatitis and/or cholecystitis | |
| CN102430009B (en) | Traditional Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN102430008B (en) | Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN104083741A (en) | Traditional Chinese medicinal composition for treating chronic gastritis and preparation method thereof | |
| CN109481515A (en) | A kind of solid dispersions effervescent tablet promoting digestive function | |
| CN100335083C (en) | Pile treating Chinese medicine prepn and its production process | |
| CN101361806B (en) | Traditional Chinese medicine formulation for treating gastrosis and preparation method thereof | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN102430075B (en) | Traditional Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN101607061A (en) | A kind of drug regimen of protecting gastric mucosa and preparation method thereof | |
| CN102416088B (en) | Chinese medicinal composition for treating gastrointestinal diseases and preparation method thereof | |
| CN118453768A (en) | A Chinese medicine composition for treating functional dyspepsia in children, and its preparation method and application | |
| CN102430010B (en) | Traditional Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN103405725B (en) | A kind of traditional Chinese medicine composition based on marine medicine for treating mammary gland hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110706 Termination date: 20151217 |
|
| EXPY | Termination of patent right or utility model |